BEDNAREK, MARIA A.,PETRONE, MARCELLA,AMBERY, PHILIP DUNCAN,JERMUTUS, LUTZ
申请号：
ARP170100613
公开号：
AR107890A1
申请日:
2017.03.10
申请国别(地区):
AR
年份:
2018
代理人:
摘要：
Methods are provided for the prevention and treatment of obesity and diabetes in patients, including the use of GLP-1 / glucon painkillers. Requirement 1: methods of weight reduction, including the administration of 100-600 mg of peptides including amino acid sequences to people in need. Hx22 qgtftsdx1 83040； sx12 X1 3 lx8309；； x1 8311；； x1 8311； x1 831222； - AX2 8304；； x2 1 square x2 3 x2 8308；； wx2 8311； - x2 831222；； gx3830404；where X² is G or S, X¹⁰ is Y or K, X¹² is K, E, R or S, X¹³ as K or Y, X¹⁵ is D or E, X¹⁶ is S or G, X¹⁷ is E, R, Q or K, X¹⁸ is R, S or A, X²⁰ is R, K or Q, X²¹ is D or E, X²³ is V or I, X²⁴ is A or Q, X²⁷ is E or V, X²⁸ is A or K and X³⁰ is G or R (SEQ ID No. 4). Claim 2: A method for reducing body fat comprising administering to a human subject in need thereof 100-600 mg of a peptide comprising the amino acid sequence of SEQ ID No. 4. Claim 17: The method of any one of the claims 1-16, wherein the peptide comprises,It is basically or consists of SEQ ID No. 19. Claim 23: methods 18-22 of any claim, wherein the second dose is 150-200 mg. Claim 30: any method of claims 25-29, wherein the third dose is 200-400 mg of peptide. Claim 47: any claimed method 1-46, i.e. synthesis of peptides by solid-phase synthesis. Claim 48: claimed approach 47en donde la s ntesis de fase s lida usa qu mica de cloruro de fluorenilmetiloxicarbonilo Reivindicaci n 54 El m todo de una cualquiera de las reivindicaciones 1 - 50 en donde el p ptido comprende un resto de estearoilo o estearato en el grupo N (psilon) where X² is G or S, X¹⁰ is Y or K, X¹² is K, E, R or S, X¹³ is K or Y, X¹⁵ is D or E, X¹⁶ is S or G, X¹⁷ is E, R, Q or K, X¹⁸ is R, S or A, X²⁰ is R, K or Q, X²¹ is D or E, X²³ is V or I, X²⁴ is A or Q, X²⁷ is E or V, X²⁸ is A or K and X³⁰ is G or R (SEQ ID No. 4).Se proporcionan métodos para prevenir y tratar la obesidad y la diabetes en pacientes, que comprenden administrar péptidos agonistas de GLP-1 / glucagón. Reivindicación 1: Un método para reducir
